Who should not use Revumenib-Revuforj?

As a new oral anti-cancer drug, Revumenib-Revuforj shows unique advantages in the treatment of acute leukemia (including AML, ALL), but it does not mean that all patients are suitable for use. The drug instructions and clinical studies have clearly pointed out that some groups of people are not recommended to use it or need to use it with special caution. First of all, the most critical category is leukemia patients who do not have KMT2A gene rearrangement. Because the drug's mechanism of action is to reverse the abnormal phenotype of leukemia cells by inhibiting the interaction between menin and the KMT2A fusion protein, patients lacking this molecular change cannot benefit from it. In other words, this drug is not a universal anti-leukemia drug, but a targeted therapy in the context of precision medicine.

Secondly, this product is not recommended for patients with decompensated hepatic insufficiency or severe renal insufficiency. Such patients often have reduced drug metabolism and clearance capabilities, which may lead to drug accumulation in the body and aggravate toxic side effects. For pregnant and lactating women, international guidelines generally recommend avoiding the use of revimenib because the potential effects of the drug on the fetus and infant are unclear, but there are speculations about risks based on the mechanism of action, so it is a contraindication. In addition, for individuals who are known to be allergic to the active ingredients or excipients of this product, severe allergic reactions may occur after use, so they are also unsuitable.

In actual clinical practice, the prescription of Revimenib requires accurate genetic testing support. After confirming that the patient hasKMT2A rearrangement or similar targets, doctors will make a judgment based on liver and kidney function, concomitant medications, and previous treatment history. Therefore, patients cannot decide whether it is suitable for use through online information, but must rely on the evaluation of professional doctors.

Reference materials:https://www.drugs.com/monograph/revumenib.html